Bayer submits first-in-class estradiol-based oral contraceptive for approval in the US
- Details
- Category: Bayer

Lundbeck strengthens its research capabilities by acquiring ground-breaking Danish technologies
- Details
- Category: Lundbeck

Top 10 Tips for Staying Healthy When Money is Tight
- Details
- Category: Eli Lilly and Company

Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
- Details
- Category: Roche

GSK further extends its product portfolio in the Middle East and North Africa
- Details
- Category: GlaxoSmithKline

Lu AA24530 shows positive results in major depressive disorder phase II study
- Details
- Category: Lundbeck

Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecules from Pfizer
- Details
- Category: Pfizer

More Pharma News ...
- Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
- Bayer files patent infringement lawsuit against Teva
- IRESSA (Gefitinib) Receives Marketing Authorisation in Europe
- Pfizer Discontinues Phase 3 Trial of Sutent® in Metastatic Colorectal Cancer
- AstraZeneca Development Partner, Pozen, Inc., Submits New Drug Application for PN400
- Bayer Schering Pharma Extends Research Portfolio in the Field of Cancer-Related Targets
- Novo Nordisk reaches settlement with the Danish authorities regarding Oil-for-Food activities